Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK)
Phase 1Most advanced trial (none active)
1Registered trials
What is Edralbrutinib?
Edralbrutinib is an orally available small molecule that covalently and irreversibly binds Bruton's tyrosine kinase (BTK), blocking B-cell antigen receptor signaling and BTK-mediated survival pathways. It is being studied in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.